Meet the New Biomarkers: Personalizing Cancer Care in 2020
  • CE

Watch this on-demand Webcast of a live CCO Webinar developed for oncology nurses to gain expert perspectives on the role of biomarker testing in the care of patients with cancer, with a focus on new and emerging molecular targets critical to the optimal treatment of lung and gastrointestinal malignancies.
Elisabeth King, RN, FNP, AGN, AOCNP
Program Director
person default
Diane Cope, PhD, ARNP-BC, AOCNP
Sara Toth, RN, MSN, FNP-C, AOCNP, AGN-BC
Registered Nurses: 1.75 Nursing contact hours
Released: July 21, 2020 Expiration: July 20, 2021
Multimedia Meet the New Biomarkers: Personalizing Cancer Care in 2020
This program is divided into short segments which you can review from the Activity landing page.
An Overview of the Current Status of Biomarker Testing in Cancer Care (23 mins)
Watch this expert overview for nurses on the role of biomarker testing in the care of patients with cancer.
Launch An Overview of the Current Status of Biomarker Testing in Cancer Care (23 mins)
New and Evolving Biomarkers in Lung Cancer (25 mins)
Gain insights for nurses on new and emerging molecular targets critical to the care of patients with lung cancer.
Launch New and Evolving Biomarkers in Lung Cancer (25 mins)
New and Evolving Biomarkers in Gastrointestinal Malignancies (27 mins)
Gain insights for nurses on new and emerging molecular targets critical to the care of patients with gastrointestinal malignancies.
Launch New and Evolving Biomarkers in Gastrointestinal Malignancies (27 mins)
Meet the New Biomarkers: Panel Discussion (25 mins)
Hear from the experts as they answer audience questions.
Launch Meet the New Biomarkers: Panel Discussion (25 mins)

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss the importance of predictive biomarkers and how they guide therapeutic decisions for patients with cancer
  • Evaluate the available data, indications, and expert recommendations to determine which biomarkers should be tested in their patients with cancer
  • Explain to patients the need for an additional biopsy to test for appropriate biomarkers in cases where the initial biopsy sample was insufficient or if the biomarker status was previously unknown
  • Evaluate the available next-generation sequencing and comprehensive genomic profiling diagnostic assays
  • Identify patients eligible to enroll on important ongoing clinical trials based on molecular testing of their tumor

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Array BioPharma Inc.
Genentech
Merck Sharp & Dohme Corp

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Elisabeth King, RN, FNP, AGN, AOCNP

Executive Director of Genomics and Precision Medicine
City of Hope
Duarte, California

Elisabeth King, RN, FNP, AGN, AOCNP, has disclosed that she has received consulting fees from Pfizer and fees for non-CME/CE services from AstraZeneca.

Faculty

Diane Cope, PhD, ARNP-BC, AOCNP

Oncology Nurse Practitioner
Chair,
Clinical Directions Team
Florida Cancer Specialists and Research Institute
Fort Myers, Florida

Diane Cope, PhD, ARNP-BC, AOCNP, has no relevant conflicts of interest to report.
Sara Toth, RN, MSN, FNP-C, AOCNP, AGN-BC

Nurse Practitioner
Director, 
APP Services
Oncology/Hematology
Texas Oncology
Fort Worth, Texas

Sara Toth, APRN, MSN, FNP-C, AOCNP, AGN-BC, has no relevant conflicts of interest to report.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Anna Poppa

Editorial Contributor

Anna Poppa has no relevant conflicts of interest to report.

The Annenberg planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for nurses and other healthcare providers who care for patients with cancer.

Goal

The goal of this activity is to improve the knowledge and competence of oncology nurses to understand and explain the use of key biomarkers to patients with cancer.

Nursing Continuing Education

Accreditation

Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

1.75 contact hours may be earned for successful completion of this activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 21, 2020, through July 20, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Downloadable slideset covering the latest data on treating patients with pancreatic cancer and BRCA mutations or other actionable alterations, from Clinical Care Options (CCO)

person default Dirk Arnold, MD, PhD Released: September 21, 2020

Downloadable slideset reviewing the latest data on molecular testing considerations for patients with pancreatic cancer, from Clinical Care Options (CCO)

Michael J. Pishvaian, MD, PhD Released: September 21, 2020

From CCO, podcast with experts discussing RET fusion–positive NSCLC, optimal testing, use of new selective RET inhibitors, and interdisciplinary communication

Dara L. Aisner, MD, PhD Joshua Bauml, MD Released: September 17, 2020

Gain key clinical insights fast with this short slideset from CCO on RET fusion–positive NSCLC

Dara L. Aisner, MD, PhD Joshua Bauml, MD Released: September 17, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?